Bronchodilator Response in Patients with COPD, Asthma-COPD-Overlap (ACO) and Asthma, Evaluated by Plethysmographic and Spirometric z-Score Target Parameters

Richard Kraemer^{1,2}Hans-Jürgen Smith³Fabian Gardin⁴Jürg Barandun⁴Stefan Minder³Lukas Kern⁵Martin H Brutsche⁵

¹Center of Pulmonary Medicine, Hirslanden Private Hospital Group, Salem-Hospital, Bern, Switzerland;

²Department of Biomedical Research, University of Bern, Bern, Switzerland;

³Medical Development, Research in Respiratory Diagnostics, Berlin, Germany;

⁴Center of Pulmonary Medicine, Hirslanden Private Hospital Group, Clinic Hirslanden, Zürich, Switzerland;

⁵Clinic of Pneumology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Background: Airflow reversibility criteria in COPD are still debated – especially in situations of co-existing COPD and asthma. Bronchodilator response (BDR) is usually assessed by spirometric parameters. Changes assessed by plethysmographic parameters such as the effective, specific airway conductance (sG_{eff}), and changes in end-expiratory resting level at functional residual capacity (FRC_{pleth}) are rarely appreciated. We aimed to assess BDR by spirometric and concomitantly measured plethysmographic parameters. Moreover, BDR on the specific aerodynamic work of breathing ($sWOB$) was evaluated.

Methods: From databases of 3 pulmonary centers, BDR to 200 g salbutamol was retrospectively evaluated by spirometric (ΔFEV_1 and ΔFEF_{25-75}), and plethysmographic (ΔsG_{eff} , ΔFRC_{pleth} , and $\Delta sWOB$) parameters in a total of 843 patients diagnosed as COPD (478 = 57%), asthma-COPD-overlap (ACO) (139 = 17%), or asthma (226 = 27%), encountering 1686 BDR-measurement-sets (COPD $n = 958$; ACO $n = 276$; asthma $n = 452$).

Results: Evaluating z-score improvement taking into consideration the whole pre-test z-score range, highest BDR was achieved by combining ΔsG_{eff} and ΔFRC detecting BDR in 62.2% (asthma: 71.4%; ACO: 56.7%; COPD: 59.8%), by ΔsG_{eff} in 53.4% (asthma: 69.1%; ACO: 51.6%; COPD: 47.4%), whereas ΔFEV_1 only distinguished in 10.6% (asthma: 21.8%; ACO: 18.6%; COPD: 4.2%). Remarkably, $\Delta sWOB$ detected BDR in 49.4% (asthma: 76.2%; ACO: 47.8%; COPD: 46.9%).

Conclusion: BDR largely depends on the pre-test functional severity and, therefore, should be evaluated in relation to the pre-test conditions expressed as Δz -scores, considering changes in airway dynamics, changes in static lung volumes and changes in small airway function. Plethysmographic parameters demonstrated BDR at a significant higher rate than spirometric parameters.

Keywords: COPD, bronchodilator response, COPD and coexisting asthma, ACO, pulmonary hyperinflation, small airways dysfunction, aerodynamic work of breathing

Introduction

Chronic obstructive pulmonary disease (COPD) is a common, complex and heterogeneous disease, characterized by airflow limitation and an increased inflammatory response of the lung.¹⁻³ The complexity refers to components with interactions, while heterogeneity is suggested because not all components are present in all patients at the same time,^{4,5} especially not over a lifetime.⁶ Bronchodilator response (BDR) – a major feature of asthma – is usually defined as an improvement of the

Correspondence: Richard Kraemer
Center of Pulmonary Medicine,
Hirslanden Private Hospital Group,
Schänzlistrasse 39, Berne, CH-3013,
Switzerland
Tel +41 79 300 26 53
Email richard.kraemer@hirslanden.ch

FEV₁, FVC, or the FEV₁/FVC-ratio, and is included as a major criterion for the diagnosis of the asthma COPD overlap (ACO).^{7–12} There is, however, still increasing evidence that explanatory power of lung function trajectories, especially FEV₁ and FVC, are poorly compelling with the complex clinical and functional facets of COPD. A staging system that could offer a composite picture of the whole pattern of functional disease severity is highly desirable.¹³ As previously proposed by both the American Thoracic Society (ATS) and the European Respiratory Society (ERS), the degree of flow limitation should be expressed by z-scores, using the lower limit of normal (LLN) for FEV₁, FVC, FEV₁/FVC ratio, and FEF_{25–75}, as cut-offs,^{14–17} identical with -1.645 z-scores, or the 5th percentiles in the distribution from which the reference values are derived. In our study also measurements of sG_{eff}, sR_{eff} and FRC_{pleth} were z-transformed, for the latter both the upper limit of normal (ULN), identical with $+1.645$ z-scores or the 95th percentiles were defined as cut-off. By that procedure the positioning of an observed measurement value within the distribution of the reference population could be obtained, and hence gender-, age-, height-, and ethnicity-specific corrected. Moreover, between-subject and age- and growth-related variability has to be taken into account.^{15,18,19} There is growing understanding that due to the enormous clinical, functional, structural, and biological heterogeneity in these patients and the changes in functional dynamics over time, a more personalized approach in diagnosing COPD and its potential subtypes is needed.⁴ There are additional features of COPD such as small airways dysfunction (SAD),^{20–23} and/or dynamic pulmonary hyperinflation (PHI),^{24–29} consistently interacting with parameters of airflow limitation, airway obstruction, and pulmonary hyperinflation. Since BDR is still considered as an important, potential phenotypic marker for several subtypes of COPD, BDR could well serve as a candidate for COPD subtyping. Admittedly, we have been interested in the evaluation of BDR not only by a single LLN level, but in a larger scope over the whole range of pre-test z-scores.

The objectives of the present study, therefore, were to evaluate BDR in a multidimensional approach, looking at an entire set of lung function parameters (spirometric and plethysmographic), expressed as z-scores in relation to the pre-test functional severity, in order to identify relevant parameters assessing BDR in relation to pre-test functional severity. Moreover, we wanted to examine BDR within

functional subgroups of COPD patients with PHI on one hand and SAD on the other hand.

Patients and Methods

Study Design and Ethics

In the present paper, we refer to retrospectively evaluated data obtained from three Swiss centers (Center of Pulmonary Diseases, Hirslanden Private Hospital Group, Salem-Hospital, Bern, Switzerland; Clinic of Pneumology, Cantonal Hospital St. Gallen, Switzerland; Center of Pulmonology, Clinic Hirslanden, Zürich, Switzerland). Patients' records were anonymized before analysis to maintain their confidentiality. The patients have been referred to the centers for extended pulmonary function testing and optimizing therapy. Data were collected from patients with a clinical diagnosis of chronic obstructive pulmonary diseases, either as (i) COPD, or patients with (ii) COPD with coexisting asthma (ACO), or (iii) bronchial asthma. The anamnestic and clinical features were assessed by experienced pulmonary physicians, based on history-taking, chest radiographs, high-resolution CT-scans, and functional investigations, such as spirometry, whole-body plethysmography, measurements of the carbon monoxide diffusion capacity (DLCO) and measurement of the fraction of exhaled nitric oxide (FeNO). COPD was defined by a history of smoking (current or ex-tobacco smokers) and a previously documented airflow limitation (FEV₁/FVC < 70%). ACO was diagnosed when the subject had features of COPD and asthma.^{7–12} Asthma was diagnosed based on symptoms such as wheezing, shortness of breath, chest tightness and cough that vary over time in their occurrence, frequency, and intensity. Patients previously diagnosed with cystic fibrosis, interstitial lung disease, pulmonary thromboembolic disease, active tuberculosis, chest wall disease, neuromuscular disorder, malignant tumor, or a history of thoracotomy with pulmonary resection, were excluded.

The study was planned according to the Federal Law of Human Research, conceptualized according to the Swiss Ethics Committees on research involving humans, and was conducted in accordance with the tenets of the Declaration of Helsinki. The study is part of the framework of the project entitled “Functional diversification of the Asthma-ACO-COPD multi-center study” (ID 2017–00259), approved by the Governmental Ethics Committee of the State of Bern, St. Gallen and Zürich (Project KEK-BE PB_2017-00104). Written informed consent was waived because of the retrospective study design, which follows

the institutional and national policies concerning research approvals. Master-files have been stored and secured in the REDCap-system of the Clinical Trial Unit, Medical Faculty, University of Berne, Switzerland.

Patients

From the database of the three centers, 843 measurement-sets fulfilled the inclusion criteria of a correctly conducted post-bronchodilator response-test to 200 µg salbutamol, defined as to be positive, if the condition ΔFEV_1 and/or $\Delta FVC \geq 12\%$, and ≥ 200 mL is fulfilled.^{15,30} These data sets were obtained from a total of 843 patients (226 patients with asthma, 26.8%; 139 patients with ACO, 16.5%; and 478 patients with COPD, 56.7%), with a mean-age of 65.7 years (min. 34.1 years, max. 89.5 years) and no significant difference between the 3 diagnostic classes.

Pulmonary Function Procedures

In the present study plethysmography including spirometry was performed using standard techniques according to ATS-ERS criteria,^{15,31} previously established and extended subsequently,^{2,32,33} using a constant-volume body plethysmograph (Master Screen Body, Erich Jaeger GmbH, Würzburg, Germany). During tidal breathing within the closed plethysmograph recordings of specific airway loops (sR_{aw} -loops) are generated, consisting of the shift volume (V_{pleth}) and the tidal flow (V'). After automated electronic loop compensation achieving “Body Temperature and Pressure Saturated” (BTPS) corrections, various parameters of airway dynamics can be computed.

The integral method of the Jaeger MasterLab software (JLab[®] and SentrySuite[®]) evaluates changes of airway dynamics as effective specific airway resistance (sR_{eff}), its reciprocal values the effective specific airway conductance (sG_{eff}), and the specific aerodynamic work of breathing (sWOB) concomitantly with changes in the end-expiratory lung volume (EELV) at FRC. Therefore, it was important that parameters of airway dynamics are assessed in the first phase of plethysmographic measurements, and hence not influenced by deep inspiration or forced breathing maneuvers or other efforts, which may influence the broncho-motor tone.^{34–37} Details regarding the sequence of plethysmographic measurements are given in [Supplemental Material Section 1](#). A special export software was developed by PanGas Ltd, Dagmersellen, Switzerland, enabling access to all routinely stored parameters in every JLab-, Sentry-Suite-databases, respectively.

Assessment of Airway Dynamics by the Integral Method

Although numerous parameters of airway dynamics can be calculated from the plethysmographic sR_{aw} -loop,³⁸ we used the approach proposed by Matthys and Orth³⁹ defining the so called “effective specific resistance” (sR_{eff}) as the ratio of the area of the shift-volume versus tidal volume ($\oint V_{pleth} dV_T$), to the area of the tidal flow/volume loop ($\oint V' dV_T$) (see [Figure S1](#)). The mathematical background of the integral technique to obtain parameters of airway dynamics (sR_{eff} , sG_{eff} , sWOB) has been previously established.^{33,39–41} Details of the methodological and mathematical approach of the so called “integral method” are given in the [Supplemental Material Section 2](#). The advantage of this integral method compared with parameters of the two-point analysis defining sR_{aw} , sG_{aw} , respectively, is that data points throughout the entire respiratory cycle are evaluated. Moreover, the integral $\oint \Delta V_{pleth} dV_T$ embodies the specific, aerodynamic work of breathing (sWOB) at rest.³⁹ Pulmonary function test data were assessed in absolute values, percentage of predicted normal values, and as z-scores according to standard prediction equations.^{18,19} For the parameters of airway dynamics (sWOB, sG_{eff} , and sR_{eff}), normative reference equations were used, recently worked out,^{42,43} and in details given in [Supplemental Material Section 3](#).

Data Analysis and Statistical Methods

Statistical analyses were performed with the IBM SPSS version 25.0 (SPSS Inc., Chicago, IL). The limit of significance was a *p*-value of 0.05. Data were transformed to z-scores as a standardized measure of the positioning of an observed measurement in the distribution of the reference population taking both between-subject as well as age- and growth-related variability into account.^{18,19} By this procedure the lower limits of normal (LLN), identical with -1.645 z-scores, or the 5th percentile in the distribution from which the reference values are derived for FEV_1 , FEF_{25-75} , sG_{eff} , as well as the upper limit of normal (ULN), identical with $+1.645$ z-scores or the 95th percentiles for FRC_{pleth} , and sWOB were obtained. The theoretical background on the Gaussian distribution, the z-score levels, and their parameter-specific pre-test z-score distribution over the whole range of z-scores are given in [Table S1](#) and [Figure S2](#) of [Supplemental Material Section 3](#).

Functional Severity

Apart from the criteria given in the last issue of GOLD to use “LLN”, “ULN” respectively as a threshold to distinguish between “normal” from “abnormal”,³ we thought it suitable to define functional severity not only based on a one-dimensional criterion, but substantiated on the individual pre-test z-scores over the whole range of baseline z-scores. The baseline values of each lung function parameter have been transferred into z-scores. This allowed the option to study the graduated individual degree of severity within different functional subtypes, such as the degree of bronchial obstruction, flow limitation, small airway dysfunction, or pulmonary hyperinflation.

Bronchodilator Response (BDR)

Apart from the condition whether the LLN (FEV_1 , FEF_{25-75} , sG_{eff}), ULN (FRC_{pleth} , $sWOB$) respectively, was reached after 400 μ g salbutamol, we developed a multi-level approach, looking for Δ z-scores of BDR within the whole range pre-test z-score distribution and hence several levels of the Gaussian z-scores, as shown in [Figure S2](#) of [Supplemental Material Section 3](#). A positive BDR was specified, if a ΔFEV_1 -z-score equivalent to ΔFEV_1 and/or $\Delta FVC \geq 12\%$, and ≥ 200 mL was achieved as predictor for the Δ z-scores of each of the other 5 parameters after bronchodilation. Based on that regression model, equivalent improvement in lung function for each parameter could be determined.

Pearson's χ^2 -test for categorical variables was performed for discriminating prevalence within patient collectives differentiating lung function within “normal” and “abnormal” ranges of airflow limitation, bronchial obstruction, small airway dysfunction and pulmonary hyperinflation, and finally for better accuracy of defining several functional subtypes in asthma versus ACO and COPD. Fisher's linear discriminant analysis was used as a classification tool to maximize the criterion function of the target parameters in the discrimination between the diagnostic classes, to define the ranking order characterizing or separating the diagnostic classes as a classifier.

Results

Prevalence of Airflow-Limitation, Bronchial Obstruction, and Dynamic Pulmonary Hyperinflation

To allow a comparison with former studies, lung function measurements were first stratified according to the baseline values, i.e. whether they lay within the range of

normal or not, the latter indicating the prevalence of each parameter ([Table 1](#)). According to the GOLD-Classification, prevalence of airflow limitation was in the global 85.2%, highest in COPD (90.6%), ACO (90.5%) respectively. Using the ATS/ERS criteria prevalence of airflow limitation was in the global 87.2%, highest in COPD (94.8%). Regarding the 5 target parameters, and taking LLN, ULN respectively as pre-test criteria of functional severity, the prevalence of airflow limitation in measurements of patients with asthma/ACO/COPD was 65.0%/86.0%/85.0% for FEV_1 ; 50.0%/70.8%/70.0% for FEF_{25-75} ; 86.3%/91.9%/87.7% for sG_{eff} ; 82.7/83.9/94.6 for $sWOB$; and 35.1%/51.1%/63.3% for FRC_{pleth} ([Table 1](#); row b). Accordingly, the highest prevalence for asthma was found by sG_{eff} and $sWOB$, for ACO by sG_{eff} and FEV_1 , and for COPD by sG_{eff} and $sWOB$. Noteworthy, a high percentage of abnormal pre-test measurements, and hence a marker for the prevalence of PHI, was found for FRC_{pleth} (53.8%), indicating that PHI was initially present in 35.1% of asthmatics, 51.1% of patients with ACO and 63.3% of patients with COPD. The percent-distribution over the 4 z-score levels representing the distribution of functional severity at pre-test (row c) shows that sG_{eff} and $sWOB$ presented with the highest allocation of functional severity in the z-score range > 2.576 SD, especially in patients with COPD (93.3%, 91.0%, respectively; rows c). No differences in the z-score distributions were found regarding gender. The quantitative distribution of pre-test z-scores is synoptically presented in [Figure 1](#). The largest z-score ranges are shown for $sWOB$ (18.9 SD) followed by sG_{eff} (13.9 SD).

Bronchodilator Response (BDR)

Results of BDR taking pre-test values of $\leq$ LLN for FEV_1 , FEF_{25-75} , sG_{eff} , and of $\geq$ ULN for FRC_{pleth} , $sWOB$ respectively as baseline starting points and hence excluding measurements within the range of normal on one hand, and individual Δ z-scores on the other hand, obtained within the 3 diagnostic classes are given in [Table 2](#). Pre-test measurements lying within ± 1.645 SD considered as “initially normal” are given in row a, showing that pre-test measurements were “initially normal” in 20.2% of FEV_1 , 35.2% of FEF_{25-75} , but only in 11.6% of sG_{eff} . Regarding $sWOB$ only 10.3% “were initially normal”, whereas FRC_{pleth} was normal in 46.2%. Noteworthy, sG_{eff} in combination with FRC_{pleth} presented only 9.3% as “initially normal”.

Table I Prevalence and Functional Severity of Lung Function Pre-Test to Bronchodilator Reversibility Test in Patients with Asthma, ACO and COPD Assessed by Various Lung Function Parameters Expressed as z-Scores

		Asthma	ACO	COPD	All	
N of all measurements (%)		226 (26.8)	136 (16.3)	480 (56.9)	842 (100)	
GOLD classification		n (%)	n (%)	n (%)		
Normal or N/A	a	67 (2.9)	13 (9.4))	45 (9.4)	125 (14.8)	165.5 (p<0.0001)
Prevalence	b	159 (70.4)	124 (90.5)	435 (90.6)	718 (85.2)	
• I	c	32 (14.2)	12 (8.8)	20 (4.2)		
• II		97 (42.9)	72 (52.6)	168 (19.9)		
• III		27 (11.9)	32 (23.4)	172 (35.8)		
• IV		3 (1.3)	8 (5.8)	75 (15.6)		
ATS/ERS classification						
At risk or N/A	a	67 (2.9)	15 (10.9)	26 (5.4)	108 (12.8)	165.5 (p<0.0001)
prevalence	b	159 (70.4)	122 (89.1)	454 (94.8)	735 (87.2)	
• Mild	c	32 (14.2)	10 (7.3)	39 (8.1)		104.8 (p<0.0001)
• Moderate		97 (42.9)	72 (52.6)	168 (35.0)		
• Severe		27 (11.9)	32 (23.4)	172 (35.8)		
• Very severe		3 (1.3)	8 (5.8)	75 (15.6)		
FEV₁		n (%)	n (%)	n (%)		
Within range of normal (≥ LLN)	a	79 (35.0)	19 (13.9)	72 (15.0)	170 (20.2)	101.9 (p<0.0001)
Flow limitation (< LLN)	b	147 (65.0)	117 (86.0)	408 (85.0)	672 (80.0)	
• z < - 1.645, ≥ -1.956 SD	c	24 (10.6)	8 (5.9)	20 (4.2)		104.8 (p<0.0001)
• z < - 1.956, ≥ -2170 SD		23 (10.2)	9 (6.6)	17 (3.5)		
• z < -2.170, ≥ -2.576 SD		36 (15.9)	24 (17.6)	52 (10.8)		
• z < -2.576 SD		64 (28.3)	76 (55.9)	319 (66.5)		
FEF_{25–75}		n (%)	n (%)	n (%)		
Within range of normal (≥ LLN)	a	113 (50.0)	39 (28.7)	144 (30.0)	296 (35.2)	39.5 (p<0.0001)
Small airway dysfunction (< LLN)	b	113 (50.0)	97 (70.8)	336 (70.0)	546 (64.8)	
• z < - 1.645, ≥ -1.956 SD	c	46 (20.4)	35 (25.5)	95 (19.8)		39.1 (p<0.0001)
• z < - 1.956, ≥ -2170 SD		21 (9.3)	18 (13.1)	67 (14.0)		
• z < -2.170, ≥ -2.576 SD		24 (10.6)	20 (14.6)	103 (21.5)		
• z < -2.576 SD		22 (9.7)	24 (17.5)	71 (14.8)		
sG_{eff}		n (%)	n (%)	n (%)		
Within range of normal (≥ LLN)	a	31 (13.7)	11 (8.1)	19 (4.0)	61 (7.2)	44.2 (p<0.0001)
Bronchial obstruction (< LLN)	b	195 (86.3)	125 (91.9)	421 (87.7)	781 (92.8)	

(Continued)

Table 1 (Continued).

		Asthma	ACO	COPD	All	
• $z < -1.645, \geq -1.956$ SD	c	3 (1.3)	0 (0)	4 (0.8)		66.1 (p<0.0001)
• $z < -1.956, \geq -2.170$ SD		3 (1.3)	3 (2.2)	2 (0.4)		
• $z < -2.170, \geq -2.576$ SD		14 (6.2)	2 (1.5)	7 (1.5)		
• $z < -2.576$ SD		175 (77.4)	120 (88.2)	448 (93.3)		
sWOB		n (%)	n (%)	n (%)		
within range of normal ($\leq$ ULN)	a	39 (17.3)	22 (16.1)	27 (5.6)	88 (10.5)	34.1 (p<0.0001)
Abnormal sWOB ($>$ ULN, all z-scores)	b	187 (82.7)	115 (83.9)	461 (96.0)	754 (89.5)	
$z > 1.645, \leq 1.956$ SD	c	2 (0.9)	1 (0.7)	4 (0.8)		36.4 (p<0.0001)
$z > 1.956, \leq 2.170$ SD		5 (2.2)	0 (0)	4 (0.8)		
$z > 2.170, \leq 2.576$ SD		5 (2.2)	1 (0.7)	8 (1.7)		
$z > 2.576$ SD		175 (77.4)	112 (82.4)	437 (91.0)		
FRC_{pleth}		n (%)	n (%)	n (%)		
within range of normal ($\leq$ ULN)	a	146 (64.9)	67 (48.9)	176 (36.7)	389 (46.2)	49.6 (p<0.0001)
Pulmonary hyperinflation ($<$ ULN)	b	79 (35.1)	70 (51.1)	304 (63.3)	453 (53.8)	
• $z > 1.645, \leq 1.956$ SD	c	12 (5.3)	10 (7.3)	25 (5.2)		64.9 (p<0.0001)
• $z > 1.956, \leq 2.170$ SD		9 (4.0)	5 (3.6)	17 (3.5)		
• $z > 2.170, \leq 2.576$ SD		17 (7.6)	12 (8.8)	34 (7.1)		
• $z > 2.576$ SD		41 (18.2)	43 (31.4)	228 (47.5)		

Notes: LLN: lower limit of normal (-1.645); ULN: upper limit of normal (1.645); z: z-scores equal to standard deviation scores (SDS) according to Gaussian distribution; a: number (n) and percent of measurements within the range of normal values predicted; b: prevalence of values within the range of normal predicted; c: distribution within z-score ranges.

Bronchodilator Response Taking LLN, ULN Respectively as Thresholds

In Table 2 (row b) BDR is presented using the criterion whether or not reaching LLN, ULN respectively, as proposed by the ERS Task force.^{15,16,31,44} BRD including all diagnostic classes could be found for all parameters in range between 10–20%.

Bronchodilator Response Assessed by Improvement Within the Whole Range of z-Scores

To find an algorithm enabling a statistically and mathematically correct comparison of BDR of all 5 lung function parameters within the 3 diagnostic groups, the ATS-ERS-criterion ($\Delta FEV_1 \geq 12\%$; ≤ 200 mL) was taken as primary criterion for sufficient BDR, corresponding to a ΔFEV_1 of z-score = $\Delta 0.778$. Equivalent thresholds were computed for each of the other parameters differentiating significantly between

“responders” and “non-responders” and the 3 diagnostic classes for each parameter (Table 2, row e; $p < 0.001$). It can be demonstrated that by the assessment evaluating BDR over the whole z-score range much higher BDR percent responses were achieved than assessed by the criteria LLN, ULN, respectively. The highest BDR was achieved by the $\Delta sWOB$ in 72.6% of measurements (asthma: 76.2%; ACO: 71.1%; COPD: 72.6%), followed by the combination of ΔsG_{eff} with ΔFRC_{pleth} in 62.2% (asthma: 71.4%; ACO: 56.7%; COPD: 59.8%). BDR by ΔFEV_1 was only seen in 10.6% of measurements (asthma: 21.8%; ACO: 18.6%; COPD: 4.2%). The differences between the two assessments of BDR are presented in row d, showing that highest differences were achieved by $\Delta sWOB$ (62.3%) followed by the combination of ΔsG_{eff} with ΔFRC_{pleth} (48.1%).

In Figure 2 the BDR, expressed as Δz -scores, obtained by each target parameter within the 3 diagnostic classes

Figure 1 The quantitative distribution of z-scores pre-test of the parameters displayed over the whole z-score pre-test range of 3 spirometric and 3 plethysmographic lung function parameters.

are given. All parameters presented with significant responses ($p < 0.001$). However, the distribution of BDR between the parameters was quite different. The most pronounced BDR was achieved by Δ sWOB (asthma: 76.6%; ACO: 72.4%; COPD: 71.1%), followed by Δ sG_{eff} (asthma: 68.7%; ACO: 68.8%; COPD: 47.3%). It was supposed that BDR could be influenced by the degree of pre-test functional severity. However, that was only the case for Δ sWOB. Noteworthy, in patients with COPD, a considerable number of patients presented BDR apart from patients with bronchial obstruction (58.1%) also by a decrease of pulmonary hyperinflation in 23.1%, or both in 18.8%. In this particular plethysmographic sub-group, BDR has been observed by Δ FEV₁ only in 5.1%.

Discussion

Findings of the Present Study

There are only a few studies reporting on a combination of spirometric and plethysmographic measurements to detect functional severity and BDR in patients with COPD.^{45–49} Jarenbäck et al. investigated the BDR based on advanced lung function parameters and brought to light that apart

from flow response, also volume response, or a combination of both, have to be identified, if BDR is to be correctly assessed in COPD.⁴⁹ Topalovic et al. and Borrill et al. demonstrated that the specific airway conductance (sG_{aw}) could be a significant factor to differentiate asthma from COPD,^{45,47} and regarding BDR, Saito et al. showed that sG_{aw} is a more sensitive measurement for detecting lung function changes in COPD patients than the more commonly used FEV₁.⁴⁸ However, to our knowledge, none of these author groups evaluated measurements assessing airway dynamic parameters by the plethysmographic integral method featuring the parameters sR_{eff}, sG_{eff}, and sWOB. If the spirometric approach is combined with a plethysmographic assessment, a profound insight into lung physiology is provided, insofar as not only the degree of flow limitation, but also the degree of bronchial obstruction and small airways dysfunction, as well as the magnitude of pulmonary hyperinflation can be estimated in COPD.

The main findings of the present study are that a combination of spirometric and plethysmographic parameters (i) enlarge the scope of evaluation of different functional deficits, within (ii) different functional severity

Table 2 Bronchodilator Response (BDR) Measured by 2 Spirometric and 3 Plethysmographic (and One Combined Plethysmographic) Lung Function Parameters Assessed by 2 Appraisals with Different Criteria Either Reaching Lower Limit of Normal (LLN), Upper Limit of Normal (ULN), or Responding Significantly Within the Whole z-Score Range, Class-Divided by Asthma, Asthma-COPD-Overlap (ACO) and COPD

	FEV ₁				FEF ₂₅₋₇₅				sG _{eff}			
	Asthma	ACO	COPD	All	Asthma	ACO	COPD	All	Asthma	ACO	COPD	All
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Pre-test within ± 1.645 SD	79 (35.0)	19 (13.8)	72 (15.1)	170 (20.2)	113 (50.0)	39 (28.3)	144 (30.1)	296 (35.2)	45 (19.9)	16 (11.6)	37 (7.7)	98 (11.6)
BDR on Criterion: LLN, ULN resp.												
• reached	46 (31.3)	19 (16.0)	31 (7.6)	96 (14.3)	40 (35.4)	15 (15.2)	27 (8.1)	82 (15.0)	55 (30.4)	13 (10.7)	30 (6.8)	98 (13.2)
• not reached	101 (68.7)	100 (84.0)	375 (92.4)	576 (85.67)	73 (64.6)	84 (84.8)	307 (91.9)	464 (85.0)	126 (69.6)	108 (89.3)	411 (93.2)	645 (86.8)
BDR on Criterion: whole z-score range												
• responder	32 (21.8)	22 (18.6)	17 (4.2)	71 (10.6)	34 (30.9)	11 (11.1)	10 (3.0)	55 (10.1)	125 (69.1)	63 (51.6)	209 (47.4)	397 (53.4)
• non-responder	115 (78.2)	97 (81.5)	389 (95.8)	601 (89.4)	79 (69.9)	88 (88.9)	324 (97.0)	49 (89.9)	56 (30.90)	59 (48.4)	232 (52.6)	347 (46.6)
BDR-differences: b) versus c)	−9.5%	2.6%	−3.4%	−3.7%	−4.5%	−4.1%	−5.1%	−4.9%	38.7%	40.9%	40.6%	40.2%
Between-subjects-effects:	BDR: F: 699 *** Diagnosis: F: 14.9 ***				BDR: F: 394 *** Diagnosis: F: 23.6 ***				BDR: F: 780 *** Diagnosis: F: 7.2 **			
• Bronchodilator response												
• Discrimination between diagnoses												
	sWOB				FRC _{pleth}				FRC _{pleth} & sG _{eff}			
	Asthma	ACO	COPD	All	Asthma	ACO	COPD	All	Asthma	ACO	COPD	All
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Pre-test within ± 1.645 SD	38 (16.8)	22 (15.9)	27 (5.6)	87 (10.3)	146 (64.6)	67 (48.6)	176 (36.8)	389 (46.2)	36 (15.9)	13 (9.4)	29 (6.1)	78 (9.3)
BDR on Criterion: LLN, ULN resp.												
• reached	37 (19.7)	9 (7.8)	32 (7.1)	78 (10.3)	27 (33.8)	11 (15.5)	40 (13.2)	77 (17.0)	61 (31.0)	14 (11.0)	35 (7.7)	110 (14.1)
• not reached	151 (80.3)	107 (92.2)	419 (92.9)	677 (89.7)	53 (67.1)	60 (84.5)	262 (86.8)	376 (83.0)	136 (69.0)	113 (89.0)	420 (53.9)	669 (85.9)
BDR on Criterion: whole z-score range												
• responder	141 (76.2)	84 (72.4)	320 (71.1)	545 (72.6)	38 (48.1)	26 (36.6)	114 (37.7)	178 (39.4)	140 (71.4)	72 (56.7)	272 (59.8)	484 (62.2)
• non-responder	44 (23.8)	32 (27.6)	130 (28.9)	206 (27.4)	41 (51.5)	45 (63.4)	188 (62.3)	274 (60.6)	56 (28.6)	55 (43.3)	183 (40.2)	294 (37.8)

BDR-differences: b) versus c)	d)	56.5%	64.6%	64.0%	62.3%	14.4%	21.1%	24.5%	22.2%	40.5%	45.7%	52.1%	48.1%
Between-discrimination: <ul style="list-style-type: none">• Bronchodilator response• Discrimination between diagnoses	e)	BDR: F: 688 *** Diagnosis: F: 4.5*											
		BDR: F: 253 *** Diagnosis: F: 3.8 n.s.											
		BDR: F: 467 *** Diagnosis: F: 8.8 **											

Notes: a) number (n) and percent of measurements within the range of normal values predicted; b) BDR based on LLN, ULN resp, pretest; c) BDR based on the whole z-score range pre-test; d) Difference of percent-BDR comparing assessment using LLN, ULN resp, with assessment using the whole z-score range; e) definition of improvement: $\Delta FEV_1 > 0.83$ l SD equal to 1 l.8; $\Delta FEF_{25-75} > 0.4$ l l SDs equal to 16.4%; $\Delta sG_{eff} > 0.895$ SDS equal to 29.3%; $\Delta sWOB > -72$ equal to -7.45%; $\Delta FRC_{pleth} < -518$ equal to -9.12%; **p < 0.001; ***p < 0.0001; *p < 0.01.

Abbreviations: BDR: bronchodilator response; LLN: lower limit of normal values predicted; ULN: upper limit of normal values predicted.

groups. Apparently, this is due to the appreciation of the whole z-score range at pre-test of different target parameters. Accordingly, (iii) BDR is distinctive for each single parameter. In consequence, our study shows that (iv) BDR largely depends on the type and degree of pre-test dysfunction⁴⁹ and, therefore, the magnitude of the BDR was greater than expected, and as previously reported.^{22,49–51} Unmistakably, it must be recognized that the overwhelming belief that COPD patients mostly present with an irreversible flow-limitation, is only based on the worldwide approach that reversibility mostly was assessed by simple spirometric measurements. There is now increasing understanding that treatment objectives should improve the function not only in central airways, but especially also in the small peripheral airways, both by improving flow and by decreasing the degree of alveolar hypoventilation, as well as decreasing air trapping and hyperinflation in COPD. Regarding BDR, it is thus important to go beyond the information provided by FEV₁, which mainly reflects flow limitation in the central airways.

Small Airways Dysfunction (SAD)

In recent years, there has been a resurgence of interest in the study of SAD from a pathophysiological viewpoint, especially as a precursor of emphysema.^{20,52} In support of this concept maximal mid-expiratory flow (MMEF) was found as a surrogate of small airways function.⁵³ Cross-sectional studies suggest that airway narrowing eventually results in a loss of airways.⁵⁴ It was anticipated that small airway disease can build up over time in peripheral zones of the lungs, without being detectable by FEV₁.⁵⁵ Regarding plethysmographic parameters, it has been anticipated that sR_{eff}, and hence its inverse, more robust measure sG_{eff}, were closely associated with symptoms of dyspnea.⁵⁶ Therefore, MMEF and hence FEF_{25–75} as well as sG_{eff} have been esteemed as reliable measures of peripheral airway function. We were interested to elaborate the interrelationship between FEF_{25–75} and sG_{eff} (both lower than LLN at pre-test) in a selective cohort of 616 measurements of patients with ACO (n = 136) and COPD (n = 480). Figure 3 demonstrates that there is a significant interrelationship between FEF_{25–75} and sG_{eff} (Figure 3A, ACO: $F = 10.2$ $p = 0.002$; COPD: $F = 120.8$ $p < 0.0001$). We like to conclude, that in contrast to sG_{aw}, obtained by the angle-technique, sG_{eff} computed by the integral method and hence considering the whole resistance

Figure 2 Bronchodilator response expressed as Δz -scores by the 5 target parameters evaluated by appraisal 3, i.e. including the whole range of pre-test z-score distribution (initial severity), as well as respecting the whole range of Gaussian distribution for calculating Δz -scores of the BDR.

Figure 3 Functional characteristics within the diagnostic classes of patients with COPD and ACO at pre-test (A) showing a significant correlation between FEF_{25-75} and sG_{eff} as surrogate of small airway function (SAD), and (B) BDR given by ΔsG_{eff} and ΔFRC_{pleth} differentiating between flow- (sG_{eff}) volume (FRC_{pleth})- and flow-volume sG_{eff} and FRC_{pleth} response.

slope, qualifies well as a parameter for central and peripheral airway function.

Pulmonary Hyperinflation (PHI)

Pulmonary hyperinflation, defined as an increased volume of air remaining in the lungs at the end of spontaneous

expiration, is present when resting FRC_{pleth} or EELV is increased above normal.^{26,27} The development of PHI in the disease course of COPD, therefore, is clinically important, mainly because it contributes to dyspnea and reduced physical activity.^{26,27} Research in recent years has clearly demonstrated that hyperinflation, at rest and/or during

exercise, is more closely associated with important clinical outcomes such as dyspnea and exercise intolerance than with expiratory flow indices.²⁶ Moreover, hyperinflation has become an important endpoint in several clinical trials evaluating the efficacy of pharmacological and non-pharmacological therapeutic approaches to COPD. Recently, a few studies have used the inspiratory capacity (IC) in relation to TLC as an indicator of static hyperinflation, since it correlated well with subjective dyspnea, exercise intolerance, and mortality in COPD patients.^{57,58} It was, however, recognized that using only IC as an indicator of a potential hyperinflation has limitations. Patients with mild airway obstruction and increased FRC_{pleth} can have an IC within the normal range. Moreover, it has to be preconceived that after deep inspirations and/or bronchodilator administration changes in the EELV at FRC may occur,³⁰ altering the distending forces of the bronchial tree, which may influence the flow in small airways, a dynamic functional aspect which has to be kept in mind.

BDR Within Functional Sub-Types in COPD

Response in Relation to Different Initial Functional Subtypes

In a subset of 842 measurements, 18.4% presented with a PHI (asthma: 28.0%; ACO: 11.0%; COPD: 16.6%), 32.0% suffered from a SAD (asthma: 49.7%; ACO: 36.7%; COPD: 23.8%), and a combination of both, was found in 49.6% (asthma: 22.3%; ACO: 52.3%; COPD: 59.6%) of abnormal pre-test measurements. Figure 3B shows that after bronchodilation the BDR can be allocated in an ΔsG_{eff} - ΔFRC_{pleth} -plot into non-responder (left upper quadrant; approximately 30%), volume-responder (left lower quadrant; in COPD 13.9%), flow responder (right upper quadrant; approximately 50%) and volume- and flow-responder (right lower quadrant; 11–14%). Noteworthy, by assessing BDR by combining airway dynamics (ΔsG_{eff}) with changes in static lung volumes (ΔFRC_{pleth}) at least 25% of patients with COPD, which would remain undetected by simple spirometry, could be identified as responders. Such findings may serve as cornerstones in future treatment concepts, since it has reliably been shown that bronchodilators reduce the degree of PHI, and hence also the work of breathing in the absence of a significant spirometric response.⁵⁹ Therefore, it is our belief that tailoring diagnostics and treatment in COPD would require that a distinction into diagnostic classes and

functional subtypes, as well as influencing confounders, must carefully be assessed, especially when asthma and COPD coexist as overlap (ACO).

Potential Sources of Mis-Qualification

For most parameters of airflow limitation and bronchial obstruction, the pre-test z-scores were < -2.576 equal to the lower left of the Gaussian distribution (0.5 percentile) mostly expressed by sG_{eff} (66.8%) compared with FEV_1 (54.6%). In other words, more than half of the patients started before bronchodilation with a severe flow-limitation prior to bronchodilation. Looking at the sWOB, it can be demonstrated that most patients (87.6%) presented with a sWOB z-score > 6.9 . This new discovery leads to the assumption that patients with the need of 5–6 times more energy for breathing pre-test at rest, are likely to be limited in their breathing capacities. Plethysmographic measurements are performed during tidal breathing, requesting only low cooperation and no coordination. It follows that severe pre-test functional derangement amplifies the specific aerodynamic work of breathing, potentially impeding the patient's coordination and cooperation for optimal forced breathing maneuvers and hence mis-qualifying baseline functional conditions. The assumption stands to reason, whether some COPD-patients with clear BDR should not be classified as ACO and hence treated accordingly. This remains assumed because it must be evaluated prospectively.

Limitations and Strengths of the Study

The present study is a retrospective evaluation of lung function data obtained by various parameters and there are no longitudinal observations, a feature that can only be achieved by a prospectively designed study. Our actual challenge was to find surrogate markers superior to FEV_1 , which is still considered as the gold standard for both the diagnosis and assessment of BDR. As it turned out, the evaluation of a potential BDR obtained by ΔsG_{eff} , and a combination of ΔsG_{eff} with ΔFRC_{pleth} as well as of by $\Delta sWOB$ disclosed a fundamentally different response archetype, which requires a new definition of lung function reversibility in COPD. The search for such alternatives is not new, as there has been a request for surrogate markers superior to FEV_1 for several years. To differentiate the functional subtypes of COPD both spirometry and plethysmography are needed. Regarding BDR, our data show that sG_{eff} is the most convincing target parameter

to define reversibility of obstruction and flow limitation in central and peripheral airways.

The main limitation of our study is that it only addresses functional trajectories representing the complex lung physiology in COPD, that are not directly linked to clinical settings. However, the aerodynamic specific work of breathing at rest (sWOB) features presumably the closest parameter associated with clinical signs such as wheezing, shortness of breath, chest tightness and cough, and could well be taken as a marker for longitudinal follow-up and treatment efficacy. Other limitations are the relatively small number of subjects per center and within the sub-groups of COPD. However, there were no differences if the centers were compared with one another (data not shown). Therefore, the population-based retrospective nature of our study and its highly standardized multicenter framework has a reliable force of expression.

Conclusion

The enormous functional, structural, and biological heterogeneity in patients with COPD implicates an assessment of target parameters evaluating interactionally flow limitation, bronchial obstruction, small airways dysfunction and pulmonary hyperinflation, graduating precisely functional severity defined by a multi-level approach with pre-test z-scores, on which standardized changes regarding BDR can be appraised. Such an approach can be helpful in the tracking of dynamics and changes over time in patients with COPD. Moreover, the distinction of different sub-phenotypes on one hand, and corresponding treatment strategies on the other hand could be provided.⁴ In view of the serious disease burden in COPD we conclude that a more sophisticated assessment of functional deficits and their reversibility is justified.

Abbreviations

ACO, asthma COPD overlap; ATS, American Thoracic Society; BDR, bronchodilator response; COPD, chronic obstructive pulmonary disease; DLCO, carbon monoxide diffusion capacity; ΔV_{pleth} , plethysmographic shift volume; EELV, end-expiratory lung volume; ERS, European Respiratory Society; FEF_{25–75}, forced expiratory flow between 25 and 75% vital capacity; FeNO, fraction of exhaled nitric oxide; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FRC_{pleth}, plethysmographic functional residual capacity; FVC, forced vital capacity; G_{aw}, airway conductance; IC, inspiratory capacity; LLN, lower limit of normal; LMM,

linear mixed model; Ln, natural logarithm; MMEF, maximal mid-expiratory flow; P_{amb}, ambient pressure; P_{H₂O}, water pressure; PHI, pulmonary hyperinflation; RV, residual volume; SAD, small airways dysfunction; SD, standard deviation; R_{aw}, airway resistance; sG_{aw}, specific airway conductance (angle method); sG_{eff}, effective specific airway conductance (integral method); sR_{eff}, effective specific airway resistance (integral method); sWOB, effective resistive work of breathing (integral method); TLC, total lung capacity; ULN, upper limit of normal; VC, vital capacity; VIF, variance inflation factor; V', flow; V_T, tidal volume.

Ethics Approval

The study was planned according to the Federal Law of Human Research, conceptualized according to the Swiss Ethics Committees on research involving humans, and was conducted in accordance with the tenets of the Declaration of Helsinki. The study is part of the framework of the project entitled “Functional diversification of the Asthma-ACO-COPD multi-center study” (ID 2017-00259), approved by the Governmental Ethics Committee of the State of Bern, St. Gallen and Zürich (Project KEK-BE PB_2017-00104). Written informed consent was waived because of the retrospective study design, which follows the institutional and national policies concerning research approvals. Master-files have been stored and secured in the REDCap-system of the Clinical Trial Unit, Medical Faculty, University of Berne, Switzerland.

Acknowledgment

We would also like to thank Sabina Gallati from the Division of Human Genetics, University of Berne for the critical reviews of the manuscripts and Mrs. Zoe Clerc, Laboratory Technician, Division of Human Genetics, University of Berne for reviewing the English style of the manuscript.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

No funding was received.

Disclosure

The authors report no conflicts of interest in this work.

References

- Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2011;184(5):507–513. doi:10.1164/rccm.201103-0405PP
- Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. *Am J Respir Crit Care Med*. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention, of chronic obstructive pulmonary disease; 2021. Available from: <https://goldcopd.org>. Accessed February 27, 2021.
- Faner R, Agusti A. Multilevel, dynamic chronic obstructive pulmonary disease heterogeneity. A challenge for personalized medicine. *Ann Am Thorac Soc*. 2016;13(Suppl 2):S466–S470. doi:10.1513/AnnalsATS.201605-372AW
- Han MK, Quirbrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. *Lancet Respir Med*. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
- Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. *Thorax*. 2013;68(7):687–690. doi:10.1136/thoraxjnl-2012-202772
- Sin DD, Miravittles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. *Eur Respir J*. 2016;48(3):664–673. doi:10.1183/13993003.00436-2016
- Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. *Chest*. 2016;149(1):45–52. doi:10.1378/chest.15-1055
- Postma DS, Rabe KF. The asthma-COPD overlap syndrome. *N Engl J Med*. 2015;373(13):1241–1249. doi:10.1056/NEJMr1411863
- Suzuki M, Makita H, Konno S, et al. Asthma-like features and clinical course of chronic obstructive pulmonary disease. An analysis from the hokkaido COPD cohort study. *Am J Respir Crit Care Med*. 2016;194(11):1358–1365. doi:10.1164/rccm.201602-0353OC
- de Marco R, Marcon A, Rossi A, et al. Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. *Eur Respir J*. 2015;46(3):671–679. doi:10.1183/09031936.00008615
- de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. *PLoS One*. 2013;8(5):e62985. doi:10.1371/journal.pone.0062985
- Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J*. 2004;23(6):932–946. doi:10.1183/09031936.04.00014304
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. *Am J Respir Crit Care Med*. 2001;163(5):1256–1276. doi:10.1164/ajrccm.163.5.2101039
- Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;26(5):948–968. doi:10.1183/09031936.05.00035205
- Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. *Thorax*. 2008;63(12):1046–1051. doi:10.1136/thx.2008.098483
- Quanjer PH, Enright PL, Miller MR, et al. The need to change the method for defining mild airway obstruction. *Eur Respir J*. 2011;37(3):720–722. doi:10.1183/09031936.00135110
- Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS workshop on lung volume measurements. Official statement of the European respiratory society. *Eur Respir J*. 1995;8(3):492–506. doi:10.1183/09031936.95.08030492
- Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med*. 1999;159(1):179–187. doi:10.1164/ajrccm.159.1.9712108
- Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350(26):2645–2653. doi:10.1056/NEJMoa032158
- Burgel PR. The role of small airways in obstructive airway diseases. *Eur Respir Rev*. 2011;20(119):23–33. doi:10.1183/09059180.00010410
- Pisi R, Aiello M, Zanini A, et al. Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2015;10:1191–1197.
- Crisafulli E, Pisi R, Aiello M, et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. *Respiration*. 2017;93(1):32–41. doi:10.1159/000452479
- O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2006;3(2):180–184. doi:10.1513/pats.200508-093DO
- O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. *Copd*. 2006;3(4):219–232. doi:10.1080/15412550600977478
- Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2014;9:187–201.
- Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. *Respir Med*. 2015;109(7):785–802. doi:10.1016/j.rmed.2015.03.010
- Park J, Lee CH, Lee YJ, et al. Longitudinal changes in lung hyperinflation in COPD. *Int J Chron Obstruct Pulmon Dis*. 2017;12:501–508. doi:10.2147/COPD.S122909
- Alter P, Orszag J, Kellerer C, et al. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. *ERJ Open Res*. 2020;6(3):92–2020. doi:10.1183/23120541.00092-2020
- Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. *Eur Respir J*. 1993;Suppl. 6(Suppl 16):5–40. doi:10.1183/09041950.005s1693
- Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
- Goldman M, Smith HJ, Ulmer WT. Lung function testing: whole-body plethysmography. *Eur Respir Mon*. 2005;31:15–43.
- Kraemer R, Smith H-J, Sigrist T, Giger G, Keller R, Frey M. Diagnostic accuracy of methacholine challenge tests assessing airway hyperreactivity in asthmatic patients - a multifunctional approach. *Respir Res*. 2016;17(1):154. doi:10.1186/s12931-016-0470-0
- Kapsali T, Permutt S, Laube B, Scichilone N, Toghias A. Potent bronchoprotective effect of deep inspiration and its absence in asthma. *J Appl Physiol*. 2000;89(2):711–720. doi:10.1152/jappl.2000.89.2.711

35. Salome CM, Thorpe CW, Diba C, Brown NJ, Berend N, King GG. Airway re-narrowing following deep inspiration in asthmatic and nonasthmatic subjects. *Eur Respir J*. 2003;22(1):62–68. doi:10.1183/09031936.03.00117502
36. Slats AM, Janssen K, van Schadewijk A, et al. Bronchial inflammation and airway responses to deep inspiration in asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2007;176(2):121–128. doi:10.1164/rccm.200612-1814OC
37. Nensa F, Marek W, Marek E, Smith HJ, Kohlhauf M. Assessment of airway hyperreactivity: comparison of forced spirometry and body plethysmography for methacholine challenge tests. *Eur J Med Res*. 2009;14(Suppl 4):170–176. doi:10.1186/2047-783X-14-S4-170
38. Ulmer WT, Marek W, Rasche K. [Airway resistance curves in obstructive respiratory tract diseases. 8 types of airway resistance curves in spontaneous respiration]. *Fortschr Med*. 1988;106(33):663–667.
39. Matthys H, Orth U. Comparative measurements of airway resistance. *Respiration*. 1975;32(2):121–134. doi:10.1159/000193642
40. Kraemer R, Baldwin DN, Ammann RA, Frey U, Gallati S. Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. *Respir Res*. 2006;7(1):138. doi:10.1186/1465-9921-7-138
41. Kraemer R, Delosea N, Ballinari P, Gallati S, Cramer R. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. *Am J Respir Crit Care Med*. 2006;174(11):1211–1220. doi:10.1164/rccm.200603-423OC
42. Kraemer R, Smith HJ, Matthys H. Normative reference equations of airway dynamics assessed by whole-body plethysmography during spontaneous breathing transitionally evaluated in infants, children and adults. *Res Sq*. 2020. doi:10.21203/rs.3.rs-39320/v1
43. Kraemer R, Smith HJ, Matthys H. Normative reference equations of airway dynamics assessed by whole-body plethysmography during spontaneous breathing evaluated in infants, children, and adults. *Physiol Rep*. In press 2021. doi:10.14814/phy2.15027
44. Bakke PS, Ronmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD. *Eur Respir J*. 2011;38(6):1261–1277. doi:10.1183/09031936.00193809
45. Borriell ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D. Measuring bronchodilation in COPD clinical trials. *Br J Clin Pharmacol*. 2005;59(4):379–384. doi:10.1111/j.1365-2125.2004.02261.x
46. Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. *Respir Physiol Neurobiol*. 2014;197:36–45. doi:10.1016/j.resp.2014.03.012
47. Topalovic M, Derom E, Osadnik CR, et al. Airways resistance and specific conductance for the diagnosis of obstructive airways diseases. *Respir Res*. 2015;16(1):88. doi:10.1186/s12931-015-0252-0
48. Saito T, Takeda A, Hashimoto K, Kobayashi A, Hayamizu T, Hagan GW. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with triPLE. *Int J Chron Obstruct Pulmon Dis*. 2015;10:2393–2404.
49. Jarenback L, Eriksson G, Peterson S, Ankerst J, Bjermer L, Tufvesson E. Bronchodilator response of advanced lung function parameters depending on COPD severity. *Int J Chron Obstruct Pulmon Dis*. 2016;11:2939–2950. doi:10.2147/COPD.S111573
50. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. *Eur Respir J*. 2008;31(4):742–750. doi:10.1183/09031936.00129607
51. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. *Thorax*. 2012;67(8):701–708. doi:10.1136/thoraxjnl-2011-201458
52. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med*. 2011;365(17):1567–1575. doi:10.1056/NEJMoa1106955
53. Stockley JA, Ismail AM, Hughes SM, Edgar R, Stockley RA, Sapay E. Maximal mid-expiratory flow detects early lung disease in α 1-antitrypsin deficiency. *Eur Respir J*. 2017;49(3):1602055. doi:10.1183/13993003.02055-2016
54. Bodduluri S, Kizhakke Puliyakote A, Nakhmani A, Charbonnier J-P. Computed tomography-based airway surface area-to-volume ratio for phenotyping airway remodeling in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2021;203(2):185–191. doi:10.1164/rccm.202004-0951OC
55. Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2016;194(2):178–184. doi:10.1164/rccm.201511-2219OC
56. Mahut B, Caumont-Prim A, Plantier L, et al. Relationships between respiratory and airway resistances and activity-related dyspnea in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2012;7:165–171.
57. French A, Balfe D, Mirocha JM, Falk JA, Mosenifar Z. The inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2015;10:1305–1312.
58. Salomon J, Stolz D, Domenighetti G, et al. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study. *Respir Res*. 2017;18(1):13. doi:10.1186/s12931-016-0498-1
59. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. *Chest*. 2002;121(4):1042–1050. doi:10.1378/chest.121.4.1042

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>